Having digitized (from paper to glass) through the late 1990s and early 2010s, the R&D community is now navigating the early adoption of digitalization and digitally enhanced workflows.
This report addresses the state of the laboratory digitalization process in 2026. While many organizations have digitized their data, obstacles to effective use of this information remain in place. Uncover the progress, pitfalls and perks of digitalization across today’s R&D landscape.
Drawing on collective insights from an audience of over 100 global organizations—including Bayer, GSK, Sanofi, Novartis, J&J, Eli Lilly, Unilever, Procter & Gamble, FMC, Chemours, and many more—the report reveals key insights, including:
- The disparity between current high priorities (AI/ML adoption) and how many organizations still struggle to centralize and digitalize the data needed to achieve these goals
- The concept of ‘digitalization maturity’—the gap between strategic intent and reality for many
- Why centralizing data benefits organizations, powering the next generation of discovery and development
Discover the state of digitalization today. Download the full report to find out more.